Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 14/20 | 0.65 |
| ▸ | CTSB | P07858 | 7/20 | 0.58 |
| ▸ | CTSL | P07711 | 7/20 | 0.58 |
| ▸ | CTSH | P09668 | 2/20 | 0.58 |
| ▸ | CTSS | P25774 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14527881 | 1.00 | CTSK (0.65) | CTSKCTSBCTSLCTSHCTSS | |
| SCHEMBL5674738 | 0.92 | CTSK (0.77) | CTSKCTSBCTSLCTSHCTSS | |
| SCHEMBL5674735 | 0.92 | CTSK (0.77) | CTSKCTSBCTSLCTSHCTSS | |
| SCHEMBL19050936 | 0.91 | CTSK (0.72) | CTSKCTSBCTSLCTSHCTSS | |
| SCHEMBL30825010 | 0.90 | CTSK (0.59) | CTSKCTSBCTSLCTSHCTSS | |
| SCHEMBL5275932 | 0.90 | CTSK (0.59) | CTSKCTSBCTSLCTSHCTSS | |
| SCHEMBL5275940 | 0.90 | CTSK (0.59) | CTSKCTSBCTSLCTSHCTSS | |
| SCHEMBL7732224 | 0.87 | CTSK (0.63) | CTSKCTSBCTSLCTSS | |
| SCHEMBL16230129 | 0.86 | CTSK (0.56) | CTSKCTSBCTSLCTSH | |
| SCHEMBL7353552 | 0.86 | CTSK (0.56) | CTSKCTSBCTSLCTSH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2738164-A1 | Synthesis of an intermediate of an antiviral compound | Dipharma Francis S.r.l. (IT) | 2014-06-04 | — | — | EP | disclosed |
| US-20140148574-A1 | SYNTHESIS OF AN INTERMEDIATE OF AN ANTIVIRAL COMPOUND | DIPHARMA FRANCIS S.R.L. (IT) | 2014-05-29 | — | — | US | disclosed |
| US-8637457-B2 | Processes and intermediates | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-01-28 | — | — | US | disclosed |
| WO-2013136265-A1 | SYNTHESIS OF AN INTERMEDIATE OF AN ANTIVIRAL COMPOUND | DIPHARMA FRANCIS S.R.L. (IT) | 2013-09-19 | — | — | WO | disclosed |
| WO-2013136265-A1 | SYNTHESIS OF AN INTERMEDIATE OF AN ANTIVIRAL COMPOUND | DIPHARMA FRANCIS S.R.L. (IT) | 2013-09-19 | — | — | WO | disclosed |
| US-8399615-B2 | Processes and intermediates | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-03-19 | — | — | US | disclosed |
| US-8383858-B2 | Processes and intermediates for preparing steric compounds | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-02-26 | — | — | US | disclosed |
| US-20100298568-A1 | Processes and intermediates for preparing steric compounds | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-11-25 | — | — | US | disclosed |
| US-7776887-B2 | producing (1S,3aR,6aS)-2-((S)-2-((S)-2-cyclohexyl-2-(pyrazine-2-carboxamido)acetamido)-3,3-dimethylbutanoyl)-N-((S)-1-(cyclopropylamino)-1,2-dioxohexan-3-yl)octahydrocyclopenta[c]pyrrole-1-carboxamide, used as serine protease inhibitors, useful for treatment of hepatitis C virus infections | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-08-17 | — | — | US | disclosed |
| US-20100174077-A1 | Processes and intermediates | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-07-08 | — | — | US | disclosed |
| US-20100063252-A1 | PROCESSES AND INTERMEDIATES | VERTEX PHARMACEUTICALS INCORPORATED | 2010-03-11 | — | — | US | disclosed |
| US-20070244334-A1 | Processes and intermediates for preparing steric compounds | VERTEX PHARMACEUTICALS INCORPORATED | 2007-10-18 | — | — | US | disclosed |
| WO-2007109023-A1 | PROCESSES AND INTERMEDIATES FOR PREPARING STERIC COMPOUNDS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-09-27 | — | — | WO | disclosed |
| US-20070087973-A1 | producing (1S,3aR,6aS)-2-((S)-2-((S)-2-cyclohexyl-2-(pyrazine-2-carboxamido)acetamido)-3,3-dimethylbutanoyl)-N-((S)-1-(cyclopropylamino)-1,2-dioxohexan-3-yl)octahydrocyclopenta[c]pyrrole-1-carboxamide, used as serine protease inhibitors, useful for treatment of hepatitis C virus infections | VERTEX PHARMACEUTICALS INCORPORATED | 2007-04-19 | — | — | US | disclosed |
| US-5733882-A | Retroviral protease inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 1998-03-31 | — | — | US | disclosed |
| EP-0602069-A4 | RETROVIRAL PROTEASE INHIBITORS. | SMITHKLINE BEECHAM CORP (US) | 1995-05-03 | — | — | EP | disclosed |
| EP-0602069-A1 | RETROVIRAL PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 1994-06-22 | — | — | EP | disclosed |
| WO-1993002057-A1 | RETROVIRAL PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 1993-02-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298568-A1 | Processes and intermediates for preparing steric compounds | REV1, HSD11B1, CYP11B1 | CTSK 2555/4885CTSB 1530/4885CTSL 2031/4885 |
| US-20140148574-A1 | SYNTHESIS OF AN INTERMEDIATE OF AN ANTIVIRAL COMPOUND | ZC3HAV1, PREP, EIF2AK2 | CTSK 132/4885CTSB 93/4885CTSL 69/4885 |
| US-20100063252-A1 | PROCESSES AND INTERMEDIATES | TFPI, SPINT2, SERPINB1 | CTSK 91/4885CTSB 49/4885CTSL 17/4885 |
| US-20070087973-A1 | producing (1S,3aR,6aS)-2-((S)-2-((S)-2-cyclohexyl-2-(pyrazine-2-carboxamido)acetamido)-3,3-dimethylbutanoyl)-N-((S)-1-(cyclopropylamino)-1,2-dioxohexan-3-yl)octahydrocyclopenta[c]pyrrole-1-carboxamide, used as serine protease inhibitors, useful for treatment of hepatitis C virus infections | PRSS1, CTRL, TMPRSS2 | CTSK 86/4885CTSB 43/4885CTSL 19/4885 |
| US-20100174077-A1 | Processes and intermediates | TFPI, SPINT2, SERPINB1 | CTSK 91/4885CTSB 49/4885CTSL 17/4885 |
| US-20070244334-A1 | Processes and intermediates for preparing steric compounds | REV1, HSD11B1, CYP11B1 | CTSK 2555/4885CTSB 1530/4885CTSL 2031/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.